Human Framework Adaptation of a Mouse Anti-Human IL-13 Antibody

Journal of Molecular Biology

Volumn 398, Issue 2, 2010, Pages 214-231

  Fransson, Johan ^a   Teplyakov, Alexey ^b   Raghunathan, Gopalan ^a   Chi, Ellen ^a   Cordier, Wendy ^a   Dinh, Thai ^a   Feng, Yiqing ^b   Giles Komar, Jill ^b   Gilliland, Gary ^b   Lollo, Bridget ^a   Malia, Thomas J ^b   Nishioka, Walter ^a   Obmolova, Galina ^b   Zhao, Shanrong ^a   Zhao, Yonghong ^b   Swanson, Ronald V ^a   Almagro, Juan C ^b  

^a 3210 Merryfield Row   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Affinity maturation; Antibody engineering; Humanization; Phage display; X ray crystallography

Indexed keywords

HYDROGEN; INTERLEUKIN 13 ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN ANTIBODY REACTION; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENETIC ENGINEERING; GERM LINE; HUMAN; HYDROGEN BOND; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 77951762065     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.03.004     Document Type: Article

References (60)

1. Almagro J.C., Fransson J. Humanization of antibodies. Front. Biosci. 2008, 13:1619-1633.
2. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl Acad. Sci. USA 1984, 81:6851-6855.
3. Mirick G.R., Bradt B.M., Denardo S.J., Denardo G.L. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q. J. Nucl. Med. Mol. Imaging 2004, 48:251-257.
4. Wagner C.L., Schantz A., Barnathan E., Olson A., Mascelli M.A., Ford J., et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev. Biol. (Basel) 2003, 112:37-53.
5. Piro L.D., White C.A., Grillo-Lopez A.J., Janakiraman N., Saven A., Beck T.M., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 1999, 10:655-661.
6. Tcheng J.E., Kereiakes D.J., Lincoff A.M., George B.S., Kleiman N.S., Sane D.C., et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001, 104:870-875.
7. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
8. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
9. Lundin J., Kimby E., Bjorkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768-773.
10. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 1989, 86:10029-10033.
11. Mottershead M., Neuberger J. Daclizumab. Expert Opin. Biol. Ther. 2007, 7:1583-1596.
12. Hwang W.Y., Almagro J.C., Buss T.N., Tan P., Foote J. Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 2005, 36:35-42.
13. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 1992, 224:487-499.
14. Acierno J.P., Braden B.C., Klinke S., Goldbaum F.A., Cauerhff A. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies. J. Mol. Biol. 2007, 374:130-146.
15. Wedemayer G.J., Patten P.A., Wang L.H., Schultz P.G., Stevens R.C. Structural insights into the evolution of an antibody combining site. Science 1997, 276:1665-1669.
16. Li Y., Li H., Yang F., Smith-Gill S., Mariuzza R. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat. Struct. Biol. 2003, 482-488.
17. Dall'Acqua W.F., Damschroder M.M., Zhang J., Woods R.M., Widjaja L., Yu J., Wu H. Antibody humanization by framework shuffling. Methods 2005, 36:43-60.
18. Barbas C.F.R., Hu D., Dunlop N., Sawyer L., Cababa D., Hendry R.M., et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl Acad. Sci. USA 1994, 91:3809-3813.
19. Hanes J., Jermutus L., Weber-Bornhauser S., Bosshard H.R., Pluckthun A. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc. Natl Acad. Sci. USA 1998, 95:14130-14135.
20. Midelfort K.S., Hernandez H.H., Lippow S.M., Tidor B., Drennan C.L., Wittrup K.D. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J. Mol. Biol. 2004, 343:685-701.
21. Hawkins R.E., Russell S.J., Baier M., Winter G. The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J. Mol. Biol. 1993, 234:958-964.
22. Hawkins R.E., Russell S.J., Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 1992, 226:889-896.
23. Lowman H.B., Bass S.H., Simpson N., Wells J.A. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry 1991, 30:10832-10838.
24. Finlay W.J., Cunningham O., Lambert M.A., Darmanin-Sheehan A., Liu X., Fennell B.J., et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J. Mol. Biol. 2009, 388:541-558.
25. Thom G., Cockroft A.C., Buchanan A.G., Candotti C.J., Cohen E.S., Lowne D., et al. Probing a protein-protein interaction by in vitro evolution. Proc. Natl Acad. Sci. USA 2006, 103:7619-7624.
26. Moy F.J., Diblasio E., Wilhelm J., Powers R. Solution structure of human IL-13 and implication for receptor binding. J. Mol. Biol. 2001, 310:219-230.
27. Heinzmann A., Mao X.Q., Akaiwa M., Kreomer R.T., Gao P.S., Ohshima K., et al. Genetic variants of IL-13 signalling and human asthma and atopy. Hum. Mol. Genet. 2000, 9:549-559.
28. Howard T.D., Whittaker P.A., Zaiman A.L., Koppelman G.H., Xu J., Hanley M.T., et al. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am. J. Respir. Cell. Mol. Biol. 2001, 25:377-384.
29. Yang G., Volk A., Petley T., Emmell E., Giles-Komar J., Shang X., et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004, 28:224-232.
30. Teplyakov A., Obmolova G., Wu S.J., Luo J., Kang J., O'Neil K., Gilliland G.L. Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607. J. Mol. Biol. 2009, 389:115-123.
31. Almagro J.C. Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J. Mol. Recognit. 2004, 17:132-143.
32. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
33. Graves P.E., Kabesch M., Halonen M., Holberg C.J., Baldini M., Fritzsch C., et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J. Allergy Clin. Immunol. 2000, 105:506-513.
34. Lefranc M.P., Clement O., Kaas Q., Duprat E., Chastellan P., Coelho I., et al. IMGT-choreography for immunogenetics and immunoinformatics. In Silico Biol. 2005, 5:45-60.
35. Lefranc M.P., Giudicelli V., Kaas Q., Duprat E., Jabado-Michaloud J., Scaviner D., et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2005, 33:D593-D597.
36. Chothia C., Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 1987, 196:901-917.
37. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., Foeller C. Sequences of Proteins of Immunological Interest 1991, Public Health Service, NIH, Washington, DC. 5th edit.
38. DeLano W.L. The PyMOL Molecular Graphics System 2009, DeLano Scientific, Palo Alto, CA.
39. Al-Lazikani B., Lesk A.M., Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 1997, 273:927-948.
40. Cunningham B.C., Wells J.A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 1989, 244:1081-1085.
41. Capra J.D., Kehoe M. Variable region sequences of five human immunoglobulin heavy chains of the VHTTI subgroup: definitive identification of four heavy chain hypervariable regions (myeloma proteins/amino acid sequences/antibody combining site). Proc. Natl Acad. Sci. USA 1974, 71:845-848.
42. Bond C.J., Wiesmann C., Marsters J.C.J., Sidhu S.S. A structure-based database of antibody variable domain diversity. J. Mol. Biol. 2005, 348:699-709.
43. Baca M., Presta L.G., O'Connor J., Wells J.A. Antibody humanization using monovalent phage display. J. Biol. Chem. 1997, 272:10678-10684.
44. Holmes M.A., Foote J. Structural consequences of humanizing an antibody. J. Immunol. 1997, 158:2192-2201.
45. H domains of immunoglobulins. J. Mol. Biol. 1990, 215:175-182.
46. Wu H., Beuerlein G., Nie Y., Smith H., Lee B.A., Hensler M., et al. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc. Natl Acad. Sci. USA 1998, 95:6037-6042.
47. Wu H., Pfarr D.S., Johnson S., Brewah Y.A., Woods R.M., Patel N.K., et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 2007, 368:652-665.
48. Yang G.H., Yoon S.O., Jang M.H., Hong H.J. Affinity maturation of an anti-hepatitis B virus PreS1 humanized antibody by phage display. J. Microbiol. 2007, 45:528-533.
49. Yoon S.O., Lee T.S., Kim S.J., Jang M.H., Kang Y.J., Park J.H., et al. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J. Biol. Chem. 2006, 281:6985-6992.
50. Padlan E.A., Abergel C., Tipper J.P. Identification of specificity-determining residues in antibodies. FASEB J. 1995, 9:133-139.
51. Chen Y., Wiesmann C., Fuh G., Li B., Christinger H.W., McKay P., et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 1999, 293:865-881.
52. Henikoff S., Henikoff J.G. Amino acid substitution matrices from protein blocks. Proc. Natl Acad. Sci. USA 1992, 89:10915-10919.
53. Gao C., Mao S., Kaufmann G., Wirsching P., Lerner R.A., Janda K.D. A method for the generation of combinatorial antibody libraries using pIX phage display. Proc. Natl Acad. Sci. USA 2002, 99:12612-12616.
54. Marks J.D., Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol. Biol. 2004, 248:161-176.
55. Ireton G.C., Stoddard B.L. Microseed matrix screening to improve crystals of yeast cytosine deaminase. Acta Crystallogr. Sect. D 2004, 60:601-605.
56. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. Sect. D 2001, 57:1373-1382.
57. Nguyen H.P., Seto N.O., MacKenzie C.R., Brade L., Kosma P., Brade H., Evans S.V. Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct. Biol. 2003, 10:1019-1025.
58. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 1997, 53:240-255.
59. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50:760-763. CCP4.
60. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 2004, 60:2126-2132.